SARS-CoV

SARS coronavirus

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

SARS-CoV Inhibitors, Modulators & Chemicals

(R)-Hydroxychloroquine

((R)-HCQ)

Cat. No.: HY-B1370B

(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial drug which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(Rac)-X77

Cat. No.: HY-136298

(Rac)-X77 is a racemate of X77. X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (**SARS-CoV-2 M^{pro}**). X77 binds to SARS-CoV-2 M^{pro} with a **K_d** value of 0.057 μM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(S)-Hydroxychloroquine

((S)-HCQ)

Cat. No.: HY-B1370A

(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine. Hydroxychloroquine, a synthetic antimalarial drug, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(±)-Alliin

((±)-L-Alliin)

Cat. No.: HY-126085

(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of **SARS-CoV-2 (M_{pro})**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

2-Hydroxyacetophenone

Cat. No.: HY-W002198

2-Hydroxyacetophenone is a principal root volatile of the Carissa edulis. 2-Hydroxyacetophenone shows inhibitory effects on infection of **HIV/SARS-CoV S pseudovirus** with an **IC_{50}** of 1.8 mM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL,

2-Hydroxycinnamic acid

Cat. No.: HY-W012531

2-Hydroxycinnamic acid is isolated from the methanol extract of Cinnamomum cassia. 2-Hydroxycinnamic acid shows inhibitory effects on infection of **HIV/SARS-CoV S pseudovirus** with an **IC_{50}** of 0.3 mM.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

3CPLro-IN-1

Cat. No.: HY-144260

3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of **SARS-CoV-2 3CLpro** with an **IC_{50}** of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive drug target for fighting COVID-19.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3CPLro-IN-2

Cat. No.: HY-144263

3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of **SARS-CoV-2 3CLpro** with an **IC_{50}** and **K_i of 1.55 and 6.09 μM, respectively**..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-O-Methylbavachalcone

Cat. No.: HY-N1910

4'-O-Methylbavachalcone is a chalcone isolated from Psoralea corylifolia, inhibits severe acute respiratory syndrome coronavirus (**SARS-CoV**) papain-like protease (**PLpro**) activity, with an **IC_{50}** of 10.1 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

6-Thioguanine

(Thioguanine; 2-Amino-6-purinethiol)

Cat. No.: HY-13765

6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (**PLpros**) and also potently inhibits **USP2** activity, with **IC_{50}**s of 25 μM and 40 μM for Plpros and recombinant human...



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Acriflavine hydrochloride

(Acriflavinium chloride hydrochloride) Cat. No.: HY-W088075

Acriflavine hydrochloride (Acriflavinium chloride hydrochloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine hydrochloride is an antiseptic. Acriflavine hydrochloride is a potent **HIF-1** inhibitor, with antitumor activity.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg

ALC-0315

Cat. No.: HY-138170

ALC-0315 is an **ionisable aminolipid** that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Aloxistatin

(E64d; E64c ethyl ester) Cat. No.: HY-100229

Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum **cysteine protease** inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amprenavir

(VX-478) Cat. No.: HY-17430

Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.09 μM.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 25 mg, 50 mg

Amprenavir-d4

Cat. No.: HY-17430S

Amprenavir-d4 is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.09 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Amprenavir-d4-1

(VX-478-d4-1) Cat. No.: HY-17430S1

Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

AMY-101

(Cp40) Cat. No.: HY-P1717

AMY-101 (Cp40), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AMY-101 acetate

(Cp40 acetate) Cat. No.: HY-P1717B

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: 99.93%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AMY-101 TFA

(Cp40 TFA) Cat. No.: HY-P1717A

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: 99.94%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

Andrographolide

(Andrographis) Cat. No.: HY-N0191

Andrographolide is a **NF-κB** inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on **p50** in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.



Purity: 98.57%
Clinical Data: Launched
Size: 100 mg, 500 mg

Ansabananin

Cat. No.: HY-145116

Ansabananin is a weak inhibitor of the ATPase activity of the **SARS Coronavirus helicase** with an IC_{50} value of 51 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-MERS-2E6 mAb

(MERS-2E6; MERS Antibody-2E6) Cat. No.: HY-P9804

Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (**CD26**), thereby inhibiting **virus** invasion into host cells.

Anti-MERS-2E6 mAb

Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-MERS-3A1 mAb

(MERS-3A1; MERS Antibody-3A1) Cat. No.: HY-P9805

Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor.

Anti-MERS-3A1 mAb

Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-MERS-D12 mAb

(MERS-D12; MERS Antibody-D12) Cat. No.: HY-P9806

Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding.

Anti-MERS-D12 mAb

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-SARS-80R mAb

(SARS-80R; SARS Antibody-80R) Cat. No.: HY-P9803

Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to **Spike (S1)** protein to prevent **SARS** virus infection of susceptible cells.

Anti-SARS-80R mAb

Purity: 95.00%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-SARS-CoV-2 Spike mAb (CR3022)

(SARS-CR3022; SARS-CoV-2 Antibody-CR3022) Cat. No.: HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein.

Anti-SARS-CoV-2 Spike mAb (CR3022)

Purity: 95.00%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-Spike-RBD mAb

(SARS-CoV-2 (2019-nCoV) Spike RBD Antibody) Cat. No.: HY-P9801

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment.

Anti-Spike-RBD mAb

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-Spike-RBD Single Domain mAb (SARS-CoV-2 (2019-nCoV)

Single-Domain Antibodies; ...) Cat. No.: HY-P9802

Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity.

Anti-Spike-RBD Single Domain mAb

Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Antiviral agent 15

Cat. No.: HY-144623

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both **rabies virus** and **pseudo-typed SARS-CoV-2** with EC_{50} values of 1.45 μM and 14.6 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiviral agent 5

Cat. No.: HY-139683

Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including **SARS-CoV-2 M^{pro}**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arteannuin B

Cat. No.: HY-N2016

Arteannuin B co-occurs with artemisinin, which is the potent antimalarial principle of the Chinese medicinal herb Artemisia annua (Asteraceae). Arteannuin B shows **anti-SARS-CoV-2** potential with an EC_{50} of 10.28 μM.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Asunaprevir

(BMS-650032)

Cat. No.: HY-14434

Asunaprevir (BMS-650032) is a potent and orally bioavailable **hepatitis C virus (HCV) NS3 protease** inhibitor, with IC_{50} of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

AT-9010

Cat. No.: HY-139165

AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of **NiRAN** (a function essential for viral replication). AT-9010 can inhibit **SARS-CoV-2** replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AT-9010 tetrasodium

Cat. No.: HY-139165A

AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of **NiRAN** (a function essential for viral replication). AT-9010 tetrasodium can inhibit **SARS-CoV-2** replication.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AT-9010 triethylamine

Cat. No.: HY-139165B

AT-9010 triethylamine, a triphosphate active metabolite of AT-527, is a potent inhibitor of **NiRAN** (a function essential for viral replication). AT-9010 triethylamine can inhibit **SARS-CoV-2** replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atazanavir

(BMS-232632)

Cat. No.: HY-17367

Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Atazanavir sulfate

(BMS-232632 sulfate)

Cat. No.: HY-17367A

Atazanavir (BMS-232632) sulfate, a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir sulfate is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Atazanavir-d5

Cat. No.: HY-17367S3

Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Atazanavir-d6

(BMS-232632-d6)

Cat. No.: HY-17367S4

Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atazanavir-d9

(BMS-232632-d9)

Cat. No.: HY-17367S2

Atazanavir-d9 (BMS-232632-d9) is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Auranofin
(SKF-39162) Cat. No.: HY-B1123

Auranofin (SKF-39162) is a thioredoxin reductase (**TrxR**) inhibitor with an **IC_{50}** of 0.2 μM. Auranofin exhibits antiviral activity against **SARS-CoV21**, with a CC_{50} of 4.2μM for monkey kidney Vero E6 cells.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Aviptadil (Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))
Cat. No.: HY-P0012

Aviptadil is an analog **vasoactive intestinal polypeptide (VIP)** with potent **vasodilatory** effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation.

Purity: 97.18%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 50 mg

Aviptadil acetate (Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine))
Cat. No.: HY-P0012A

Aviptadil acetate is an analog **vasoactive intestinal polypeptide (VIP)** with potent **vasodilatory** effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation.

Purity: 99.09%
Clinical Data: Launched
Size: 5 mg, 10 mg

Azelastine
Cat. No.: HY-B0462A

Azelastine, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azelastine hydrochloride
Cat. No.: HY-B0462

Azelastine hydrochloridem, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Azelastine-13C,d3
Cat. No.: HY-B0462AS

Azelastine-13C,d3 is deuterium labeled Azelastine. Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azelastine-13C-d3 hydrochloride
Cat. No.: HY-B0462S

Azelastine-13C-d3 hydrochloride is the 13C- and deuterium labeled Azelastine hydrochloride. Azelastine hydrochloridem, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bananin
Cat. No.: HY-145113

Bananin is an effective inhibitor of the ATPase activity of the **SARS Coronavirus helicase** with an **IC_{50}** value of 2.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bemnifosbuvir
(AT-511) Cat. No.: HY-137958A

Bemnifosbuvir (AT-511) is a potent and orally active **HCV viral replication** inhibitor. Bemnifosbuvir is highly effective in the control of **SARS-CoV-2 (COVID-19)** infection in vitro (**EC_{90}**=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Bemnifosbuvir hemisulfate
(AT-527) Cat. No.: HY-137958

Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active **HCV viral replication** inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of **SARS-CoV-2 (COVID-19)** infection in vitro (**EC_{90}**=0.47 μM).



Purity: 99.33%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Boceprevir

(EBP 520; SCH 503034) Cat. No.: HY-10237

Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with a K_i of 14 nM in both enzyme assay and an EC_{90} of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 97.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Boceprevir-d9

(EBP 520-d9; SCH 503034-d9) Cat. No.: HY-10237S

Boceprevir-d9 (EBP 520-d9) is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with a K_i of 14 nM in both enzyme assay and an EC_{90} of 350 nM in cell-based replicon assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bonducellpin D

Cat. No.: HY-N2949

Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against **SARS-CoV** M^{pro} and **MERS-CoV** M^{pro}, with an K_i of 467.11 and 284.86 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Brequinar

(DUP785; NSC 368390) Cat. No.: HY-108325

Brequinar (DUP785) is a potent inhibitor of **dihydroorotate dehydrogenase (DHODH)** with an IC_{50} of 5.2 nM for **human DHODH**. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-**SARS2** activity.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bromhexine hydrochloride

Cat. No.: HY-B0372A

Bromhexine hydrochloride is a potent and specific **TMPRSS2** protease inhibitor with an IC_{50} of 0.75 μM. Bromhexine hydrochloride can prevent and manage **SARS-CoV-2** infection. Bromhexine hydrochloride is an **autophagy** agonist.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Bromhexine-d3 hydrochloride

Cat. No.: HY-B0372AS

Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Camostat mesylate

(Camostat mesilate; FOY305; FOY-S980) Cat. No.: HY-13512

Camostat mesylate (Camostat mesilate) is an orally active, synthetic **serine protease** inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of **TMPRSS2**, shows antiviral activity against **SARS-CoV-2**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Carmofur

(HCFU) Cat. No.: HY-B0182

Carmofur (HCFU), a derivative of 5-Fluorouracil, is an antineoplastic agent. Carmofur is an inhibitor of **acid ceramidase** with an IC_{50} of 79 nM for the rat enzyme. Carmofur inhibits the SARS-CoV-2 main protease (Mpro).



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

CCF0058981

(CCF981) Cat. No.: HY-132306

CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent **SARS-CoV-2** $3CL^{pro}$ **(SC2)** inhibitor with an IC_{50} of 68 nM. CCF0058981 inhibits **SC1 (SARS-CoV-1** $3CL^{pro}$**)** with an IC_{50} of 19 nM. CCF0058981 has **antiviral** efficacy and has the potential for COVID-19 research.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cepharanthine

Cat. No.: HY-N6972

Cepharanthine is a natural product isolated from the plant StephaniacephalanthaHayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activity.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Chebulagic acid

Cat. No.: HY-N1996



Chebulagic acid is a **COX-LOX** dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a **M2 serine to asparagine 31 mutation (S31N)** inhibitor and influenza antiviral.

Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Chloroquine

Cat. No.: HY-17589A



Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.

Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine dihydrochloride

Cat. No.: HY-17589B



Chloroquine dihydrochloride is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Chloroquine phosphate

Cat. No.: HY-17589



Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.

Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine-d4 phosphate

Cat. No.: HY-17589S1



Chloroquine-d4 phosphate is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chloroquine-d5

Cat. No.: HY-17589AS



Chloroquine D5 is deuterium labeled Chloroquine. Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chloroquine-d5 diphosphate

Cat. No.: HY-17589S



Chloroquine-d5 diphosphate is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cichoriin

Cat. No.: HY-N8599



Cichoriin is an active compounds against **SARS-CoV-2**, and may be a potential candidate in treating severe COVID-19.

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cleistanthin B

(Diphyllin O-glucoside)

Cat. No.: HY-N9351



Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC_{50} of 6.51 μM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo.

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Coronastat

(NK01-63)

Cat. No.: HY-147020



Coronastat is a potent inhibitor of the **SARS-CoV-2 3CL protease**. The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Danoprevir

(ITMN-191; R7227; RO5190591; RG7227) Cat. No.: HY-10238



Danoprevir (ITMN-191) is an orally active **NS3/4A protease** inhibitor for hepatitis C virus (HCV) with an IC_{50} of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC_{50} higher than 10 μM).

Purity: 98.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dexamethasone

(Hexadecadrol; Prednisolone F) Cat. No.: HY-14648



Dexamethasone (Hexadecadrol) is a **glucocorticoid receptor** agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes.

Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dexamethasone-4,6α,21,21-d4

Cat. No.: HY-14648S3



Dexamethasone-4,6α,21,21-d4 is the deuterium labeled Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dexamethasone-d4

(Hexadecadrol-d4; Prednisolone F-d4) Cat. No.: HY-14648S2



Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dexamethasone-d5

(Hexadecadrol-d5; Prednisolone F-d5) Cat. No.: HY-14648S



Dexamethasone-d5 (Hexadecadrol-d5) is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a **glucocorticoid receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Dexamethasone-d5-1

(Hexadecadrol-d5-1; Prednisolone F-d5-1) Cat. No.: HY-14648S1



Dexamethasone-d5-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydrotanshinone I

Cat. No.: HY-N0360



Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.

Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Direct Violet 1

Cat. No.: HY-D1270



Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the **SARS-CoV-2 spike protein** and **ACE2** inhibitor with IC_{50}s of 1.47-2.63 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

E 64c

Cat. No.: HY-100227



E 64c is a derivative of naturally occurring epoxide inhibitor of **cysteine proteases**, a Calcium-activated neutral protease **(CANP)** inhibitor and a very weak irreversible **cathepsin C** inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EIDD-1931

(β-D-N4-hydroxycytidine; NHC) Cat. No.: HY-125033



EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent **anti-virus agent**. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).

Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Emodin

(Frangula emodin) Cat. No.: HY-14393

Emodin (Frangula emodin), an anthraquinone derivative, is an anti-**SARS-CoV** compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits **casein kinase-2** (**CK2**). Anti-inflammatory and anticancer effects.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Emodin-d4

(Frangula emodin-d4) Cat. No.: HY-14393S

Emodin-d4 (Frangula emodin-d4) is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-**SARS-CoV** compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Ensitrelvir

(S-217622) Cat. No.: HY-143216

Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, **SARS-CoV-2 3CL protease** inhibitor (IC_{50}=13 nM).



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ensitrelvir fumarate

(S-217622 fumarate) Cat. No.: HY-143216A

Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, **SARS-CoV-2 3CL protease** inhibitor (IC_{50}=13 nM).



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Eubananin

Cat. No.: HY-145118

Eubananin is an effective inhibitor of the ATPase activity of the **SARS Coronavirus helicase** with an IC_{50} value of 2.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FASN-IN-4

Cat. No.: HY-12648

FASN-IN-4 is a potent inhibitor of fatty acid synthase (**FASN**) with an IC_{50} of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 also inhibits **SARS-CoV-2** with an EC_{50} of 18.6nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg

FASN-IN-4 tosylate

Cat. No.: HY-12648A

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (**FASN**) with an IC_{50} of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 tosylate also inhibits **SARS-CoV-2** with an EC_{50} of 18.6nM.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Favipiravir

(T-705) Cat. No.: HY-14768

Favipiravir (T-705) is a potent viral **RNA polymerase** inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP).



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FOY 251

Cat. No.: HY-19727A

FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a **proteinase** inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

FOY 251 free base

Cat. No.: HY-19727

FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a **proteinase** inhibitor. FOY 25 free base inhibits SARS-CoV-2 infection in cells assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FWM-3

Cat. No.: HY-146987

FWM-3 is a potent **SARS-CoV-2 NSP13 helicase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galidesivir

(BCX4430; Immucillin-A) Cat. No.: HY-18649A

Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral **RNA-dependent RNA polymerase (RdRp)** activity.



Purity: 99.29%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Galidesivir hydrochloride

(BCX4430 hydrochloride; Immucillin-A hydrochloride) Cat. No.: HY-18649

Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral **RNA-dependent RNA polymerase (RdRp)** activity.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gallinamide A

Cat. No.: HY-N10109

Gallinamide A is a potent inhibitor of **cathepsin L** with an IC_{50} value of 17.6 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Glecaprevir

(ABT-493) Cat. No.: HY-17634

Glecaprevir is a novel **HCV NS3/4A protease** inhibitor, with IC_{50} values ranging from 3.5 to 11.3 nM. Glecaprevir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 4.09 μM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF-2

Cat. No.: HY-11007

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of **Bcr-Abl**. GNF-2 inhibits Ba/F3.p210 proliferation with an IC_{50} of 138 nM .



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNF-5

Cat. No.: HY-15738

GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Grazoprevir

(MK-5172) Cat. No.: HY-15298

Grazoprevir (MK-5172) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir hydrate

(MK-5172 hydrate) Cat. No.: HY-15298B

Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir potassium salt

(MK-5172 potassium salt) Cat. No.: HY-15298A

Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.40%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir sodium salt

(MK-5172 sodium salt) Cat. No.: HY-15298C

Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

GRL-0496

Cat. No.: HY-137954

GRL-0496 is a potent chloropyridyl ester-derived **SARS-CoV 3CLpro** inhibitor, with an IC_{50} of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows **SARS-CoV** antiviral activity, with an EC_{50} of 6.9 μM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GRL0617

Cat. No.: HY-117043

GRL0617 is a potent, selective and competitive noncovalent inhibitor of **severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro)/deubiquitinase**, with an IC_{50} of 0.6 μM, and with a K_i of 0.49 μM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GS-441524

Cat. No.: HY-103586

GS-441524, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus.



Purity: 99.77%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GS-443902

(GS-441524 triphosphate; Remdesivir metabolite) Cat. No.: HY-126303

GS-443902 (GS-441524 triphosphate) is a potent viral **RNA-dependent RNA-polymerases (RdRp)** inhibitor with IC_{50}s of 1.1 μM, 5 μM for **RSV** RdRp and **HCV** RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GS-443902 trisodium (GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium)

Cat. No.: HY-126303C

GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral **RNA-dependent RNA-polymerases (RdRp)** inhibitor with IC_{50}s of 1.1 μM, 5 μM for **RSV** RdRp and **HCV** RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).



Purity: 99.98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GS-621763

Cat. No.: HY-145119

GS-621763, an orally bioavailable prodrug of GS-441524, shows antiviral activity against **SARS-CoV-2** pathogenesis in mice.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Guanosine triphosphate

(GTP) Cat. No.: HY-113225

Guanosine triphosphate is a native **nucleotide**. The derivatives of GTP may be used as specific inhibitors against COVID-19.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCoV-229E-IN-1

Cat. No.: HY-132169

HCoV-229E-IN-1 is a potent inhibitor of **HCoV-229E** replication, with an EC_{50} of 0.65 μM and 0.6 μM in MTS and CPE cells, respectively.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HeE1-2Tyr

Cat. No.: HY-100749

HeE1-2Tyr, a pyridobenzothiazole compound, is a **flavivirus RNA dependent RNA polymerases (RdRp)** inhibitor. HeE1-2Tyr significantly inhibits **West Nile**, **Dengue** and **SARS-CoV-2 RdRps** (IC_{50} of 27.6 μM) activity in vitro.



Purity: 96.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hispidulin 4'-O-β-D-glucopyranoside

Cat. No.: HY-N8205

Hispidulin 4'-O-β-D-glucopyranosid, a natural compound, may serve as a potential COVID-19 main protease inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Hydroxychloroquine

Cat. No.: HY-W031727

Hydroxychloroquine is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling. Hydroxychloroquine is efficiently inhibits **SARS-CoV-2** infection in vitro.



Purity: ≥97.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroxychloroquine sulfate

(HCQ sulfate)

Cat. No.: HY-B1370

Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling. Hydroxychloroquine sulfate is efficiently inhibits **SARS-CoV-2** infection in vitro.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Hydroxychloroquine-d4 sulfate

(HCQ-d4 sulfate)

Cat. No.: HY-B1370S

Hydroxychloroquine-d4 sulfate (HCQ-d4 sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxychloroquine-d4-1 sulfate

Cat. No.: HY-W031727S

Hydroxychloroquine-d4-1 sulfate is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling. Hydroxychloroquine is efficiently inhibits **SARS-CoV-2** infection in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Hydroxyethylamine

Cat. No.: HY-144747

Hydroxyethylamine (Compd VII) is a **SARS-CoV-2 3CLpro** inhibitor with an IC_{50} of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib-d8

(STI571-d8; CGP-57148B-d8)

Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Imiquimod

(R 837)

Cat. No.: HY-B0180

Imiquimod (R 837), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.



Purity: 99.96%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Imiquimod hydrochloride

(R 837 hydrochloride) Cat. No.: HY-B0180A

Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Imiquimod maleate

(R 837 maleate) Cat. No.: HY-B0180B

Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Imiquimod-d6

(R 837-d6) Cat. No.: HY-B0180S

Imiquimod-d6 (R 837-d6) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod exhibits antiviral and antitumor effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imiquimod-d9

(R 837-d9) Cat. No.: HY-B0180S1

Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indinavir sulfate

(MK-639 sulfate; L735524 sulfate) Cat. No.: HY-B0689A

Indinavir sulfate(MK-639 sulfate; L735524 sulfate) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Indinavir sulfate is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC$_{50}$** of 1.71 μM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

INSCoV-600K(1)

Cat. No.: HY-144063

INSCoV-600K(1) is a potent inhibitor of **M^{pro}** (**3CL^{pro}**). Proteases (PL ^{pro} and 3CL ^{pro}) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

INSCoV-601I(1)

Cat. No.: HY-144061

INSCoV-601I(1) is a potent inhibitor of **M^{pro}** (**3CL^{pro}**). Proteases (PL ^{pro} and 3CL ^{pro}) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

INSCoV-614(1B)

Cat. No.: HY-144062

INSCoV-614(1B) is a potent inhibitor of **M^{pro}** (**3CL^{pro}**). Proteases (PL ^{pro} and 3CL ^{pro}) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iodobananin

Cat. No.: HY-145114

Iodobananin is an effective inhibitor of the ATPase activity of the **SARS Coronavirus helicase** with an **IC$_{50}$** value of 0.54 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivermectin

(MK-933) Cat. No.: HY-15310

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of **Impα/β1-mediated nuclear import** and has potent antiviral activity towards both HIV-1 and dengue virus.



Purity: 96.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Ivermectin B1a

Cat. No.: HY-126937

Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310). Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 5 mg

Ivermectin B1b

Cat. No.: HY-125729

Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

Kansuinine B

Cat. No.: HY-126420

Kansuinine B inhibits IL-6-induced Stat3 activation. Kansuinine B possesses anti-viral activity and could be used in the study for COVID-19.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Kobophenol A

Cat. No.: HY-126419

Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC_{50} of 1.81 μM and inhibits **SARS-CoV-2** viral infection in cells with an EC_{50} of 71.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KW-8232

Cat. No.: HY-100304A

KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of **PGE2**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-8232 free base

Cat. No.: HY-100304

KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of **PGE2**.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 1 mg

Ledipasvir

(GS-5885)

Cat. No.: HY-15602

Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50}s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 1.62 μM.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir-d6

(GS-5885-d6)

Cat. No.: HY-15602S

Ledipasvir-d6 (GS-5885-d6) is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50}s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lopinavir

(ABT-378)

Cat. No.: HY-14588

Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease**, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Lopinavir-d8

Cat. No.: HY-14588S1

Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease**, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Lufotrelvir

(PF-07304814) Cat. No.: HY-138078

Lufotrelvir (PF-07304814), a phosphate prodrug of PF-00835231, acts as a potent **3CL^{pro} protease (M^{pro})** inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CL^{pro} activity with a **K_i** of 174nM.



Purity: 99.90%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg

Mefloquine hydrochloride

(Mefloquin hydrochloride) Cat. No.: HY-17437A

Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-**SARS-CoV-2** entry inhibitor. Mefloquine hydrochloride is also a **K^+ channel (KvQT1/minK)** antagonist with an **IC_{50}** of ~1 μM.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Merafloxacin

(CI-934) Cat. No.: HY-139010

Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective **programmed -1 ribosomal frameshifting (-1 PRF)** inhibitor of **beta coronaviruses**. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MERS-CoV-IN-1

Cat. No.: HY-139908

MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1).



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Methylprednisolone

(U 7532) Cat. No.: HY-B0260

Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical **COVID-19** by activating **ACE2** and reducing IL-6 levels.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methylprednisolone-d2

(U 7532-d2) Cat. No.: HY-B0260S4

Methylprednisolone-d2 is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylprednisolone-d3

(U 7532-d3) Cat. No.: HY-B0260S

Methylprednisolone-d3 (U 7532-d3) is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylprednisolone-d4

(U 7532-d4) Cat. No.: HY-B0260S2

Methylprednisolone-d4 is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylprednisolone-d5

(U 7532-d5) Cat. No.: HY-B0260S1

Methylprednisolone-d5 (U 7532-d5) is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylprednisolone-d7

(U 7532-d7) Cat. No.: HY-B0260S3

Methylprednisolone-d7 is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mizoribine

(NSC 289637; HE 69)

Cat. No.: HY-17470

Mizoribine (NSC 289637), an imidazole nucleoside, inhibits **HCV** RNA replication with IC_{50} of approximately 100 μM for anti-HCV activity. Immunosuppressant.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

ML188

Cat. No.: HY-136259

ML188, a first in class probe, is a selective non-covalent SARS-CoV **3CLpro** inhibitor with an **IC_{50}** of 1.5 μM. Antiviral activity.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Molnupiravir

(EIDD-2801; MK-4482)

Cat. No.: HY-135853

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against **influenza virus** and multiple **coronaviruses**, such as **SARS-CoV-2**, **MERS-CoV**, **SARS-CoV**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Mpro inhibitor N3 hemihydrate

Cat. No.: HY-136149A

Mpro inhibitor N3 hemihydrate is a potent inhibitor of **SARS-CoV-2 Mpro** with an EC_{50} of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg

Nafamostat

Cat. No.: HY-B0190

Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nafamostat hydrochloride

Cat. No.: HY-B0190B

Nafamostat hydrochloride, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat hydrochloride supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat hydrochloride blocks activation of SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nafamostat mesylate

(FUT-175)

Cat. No.: HY-B0190A

Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat mesylate supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat mesylate blocks activation of SARS-CoV-2.



Purity: 98.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Narlaprevir

(SCH 900518)

Cat. No.: HY-10300

Narlaprevir (SCH 900518) is a selective and orally bioavailable **NS3 protease** inhibitor with a **K_i** value of 6 nM and an **EC_{90}** value of 40 nM. Narlaprevir also inhibits the **HCV nonstructural protein 3 serine protease**.



Purity: 98.15%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

NHC-diphosphate

Cat. No.: HY-135867D

NHC-diphosphate is an active phosphorylated intracellular **metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC is a pyrimidine ribonucleoside and behaves as a potent **anti-virus agent**.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NHC-diphosphate triammonium

Cat. No.: HY-135867F

NHC-triphosphate triammonium is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NHC-triphosphate

Cat. No.: HY-135867

NHC-triphosphate is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the **viral polymerase** and can be incorporated into **HCV** replicon RNA.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg

NHC-triphosphate tetraammonium

Cat. No.: HY-135867E

NHC-triphosphate tetraammonium is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form.



Purity: 96.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Niazinin

Cat. No.: HY-N8471

Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC_{50} value of 5.25 μM. Niazinin also shows a binding affinity with the target protein **3CL protease**. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Nirmatrelvir

(PF-07321332)

Cat. No.: HY-138687

Nirmatrelvir (PF-07321332) is a potent and orally active **SARS-CoV 3C-like protease ($3CL^{PRO}$)** inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

NK007

Cat. No.: HY-N10118

NK007 is a novel anti-SARS-CoV-2 agent with an EC_{50} value of 30 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

ONO-5334

Cat. No.: HY-108044

ONO-5334 is a potent, selective and orally active **cathepsin K** inhibitor with K_i values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg

Paritaprevir

(ABT-450; Veruprevir)

Cat. No.: HY-12594

Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (**NS3/4A**) protease inhibitor with EC_{50}s of 1 and 0.21 nM against **HCV** 1a and 1b, respectively. Paritaprevir is also a **SARS-CoV $3CL^{pro}$** inhibitor with an IC_{50} of 1.31 μM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PB28

Cat. No.: HY-108511A

PB28 is a cyclohexylpiperazine derivative and a high affinity and selective **sigma 2 (σ2) receptor** agonist with a K_i of 0.68 nM. PB28 is also a **σ1** antagonist with a K_i of 0.38 nM. PB28 is less affinity for other receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PB28 dihydrochloride

Cat. No.: HY-108511

PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective **sigma 2 (σ2) receptor** agonist with a K_i of 0.68 nM. PB28 dihydrochloride is also a **σ1** antagonist with a K_i of 0.38 nM.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PF-00835231

Cat. No.: HY-137048

PF-00835231 is a CoV-2 **cysteine 3C-like protease ($3CL^{pro}$)** inhibitor, with IC_{50}s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 $3CL^{pro}$, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Plitidepsin

(Aplidine)

Cat. No.: HY-16050

Aplidine (Plitidepsin) is a potent anti-cancer agent by targeting **eEF1A2** (K_D=80nM). Aplidine possesses antiviral activity and is against **SARS-CoV-2** with an IC_{90} of 0.88 nM.



Purity: 99.88%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

PLpro inhibitor

Cat. No.: HY-17542

PLpro inhibitor is a potent inhibitor of **papain-like protease (PLpro)** with an IC_{50} of 2.6 μM. PLpro inhibitor inhibits **SARS-CoV-2 PLpro** with an IC_{50} of 5.0 μM and an EC_{50} of 21.0 μM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pradimicin A

Cat. No.: HY-132191

Pradimicin A (PRM-A) is a potent antifungal agent, with an **MIC** of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca^{2+} ion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Proxalutamide

(GT0918; Pruxelutamide)

Cat. No.: HY-103184

Proxalutamide (GT0918) is an orally active potent **androgen receptor (AR)** antagonist. Proxalutamide (GT0918) can be used in the study for prostate cancer and COVID-19.



Purity: 98.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Punicalagin

Cat. No.: HY-N0063

Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive **3CL^{pro}** inhibitor and inhibits **SARS-CoV-2** replication in vitro.



Purity: 99.90%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 20 mg

RdRP-IN-2

Cat. No.: HY-139442

RdRP-IN-2 is a **RNA dependent RNA polymerase (RdRp)** inhibitor. RdRP-IN-2 significantly inhibits **SARS-CoV-2 RdRp** with an IC_{50} of 41.2 μM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

rel-Zotatifin

(rel-eFT226)

Cat. No.: HY-112163A

rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated **eIF4A** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Remdesivir

(GS-5734)

Cat. No.: HY-104077

Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC_{50}s of 74 nM for **SARS-CoV** and **MERS-CoV** in HAE cells, and 30 nM for **murine hepatitis virus** in delayed brain tumor cells.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Remdesivir impurity 9-d4

Cat. No.: HY-104077S2

Remdesivir impurity 9-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Remdesivir nucleoside monophosphate

Cat. No.: HY-44358

Remdesivir nucleoside monophosphate is a metabolite of Remdesivir. Remdesivir is a nucleoside analogue with effective antiviral activity against SARS-CoV and MERS-CoV.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 5 mg

Remdesivir O-desphosphate acetonide impurity

Cat. No.: HY-136597

Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Remdesivir-d4

(GS-5734-d4)

Cat. No.: HY-104077S1

Remdesivir-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Remdesivir-d5

(GS-5734-d5)

Cat. No.: HY-104077S

Remdesivir-D5 (GS-5734-D5) is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with **EC_{50}**s of 74 nM for **SARS-CoV** and **MERS-CoV** in HAE cells, and 30 nM for **murine hepatitis virus** in delayed brain tumor cells.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg

Ritonavir

(ABT 538; RTV)

Cat. No.: HY-90001

Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.61 μM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Ritonavir-13C,d3

(ABT 538-13C,d3; RTV-13C,d3)

Cat. No.: HY-90001S1

Ritonavir-13C,d3 (ABT 538-13C,d3) is the 13C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.61 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ritonavir-d6

Cat. No.: HY-90001S

Ritonavir-d6 (ABT 538-d6) is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.61 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saquinavir

(Ro 31-8959)

Cat. No.: HY-17007

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.36 μM.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Saquinavir-d9

Cat. No.: HY-17007S

Saquinavir-d9 (Ro 31-8959-d9) is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.36 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

SARS-CoV MPro-IN-1

Cat. No.: HY-136606

SARS-CoV MPro-IN-1 is a **SARS-CoV-2 3CLpro** covalent inhibitor, with an **IC_{50}** of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC_{50} of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV MPro-IN-2

Cat. No.: HY-N144101

SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of **SARS-CoV-2 M^{pro}** with an **IC_{50}** value of 72.07 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2 3CLpro-IN-1

Cat. No.: HY-144833

SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of **SARS-CoV-2 3CL^{pro}**. 3CL^{pro} (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral drugs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2 3CLpro-IN-2

Cat. No.: HY-146998

SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2 Mpro-IN-1

Cat. No.: HY-144464

SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective and irreversible inhibitor of **SARS-CoV-2 main protease (Mpro)**, with an **IC_{50}** of 116 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-1

Cat. No.: HY-135860

SARS-CoV-2-IN-1 is a potent **Mpro** inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with **IC_{50}**s of 0.67, 0.90 and 0.58 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-10

Cat. No.: HY-145276

SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of **SARS-CoV-2 3CL protease** (**3CLpro**) with an **IC_{50}** and **EC_{50}** of 0.13 and 1.03 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-11

Cat. No.: HY-145277

SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of **SARS-CoV-2 3CL protease** (**3CLpro**) with an **IC_{50}** and **EC_{50}** of 0.17 and 1.45 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-13

Cat. No.: HY-144770

SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of **SARS-CoV-2** with an **IC_{50}** of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-14

Cat. No.: HY-144771

SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of **SARS-CoV-2** with an **IC_{50}** of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-15

Cat. No.: HY-144772

SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of **SARS-CoV-2** with an **IC_{50}** of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-18

Cat. No.: HY-143470

SARS-CoV-2-IN-18 (Compound 26) is a potent **SARS-CoV-2 3C-like protease** inhibitor with an **IC_{50}** of 45 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-19

Cat. No.: HY-146379

SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of **SARS-CoV-2** with an EC_{50} of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-20

Cat. No.: HY-146381

SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of **SARS-CoV-2** with an EC_{50} of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-21

Cat. No.: HY-147516

SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent **SARS-CoV-2 main protease** inhibitor, with an IC_{50} of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-6

Cat. No.: HY-132886

SARS-CoV-2-IN-6 is a **SARS-CoV-2 3CLpro** inhibitor that shows the most potent enzyme inhibitory IC_{50} value of 73 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SARS-CoV-2-IN-7

Cat. No.: HY-141841

SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC_{50} value (844 nM) in SARS-CoV-2-infected Vero E6 cells.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SARS-CoV-2-IN-8

Cat. No.: HY-139732

SARS-CoV-2-IN-8 is a **SARS-CoV-2** main protease inhibitor with an IC_{50} value of 0.75 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-2-IN-9

Cat. No.: HY-139866

SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in **SARS-CoV-2** main protease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SARS-CoV-IN-1

Cat. No.: HY-135855

SARS-CoV-IN-1 is an effective inhibitor of **SARS-CoV** replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC_{50} of 4.9 μM in Vero cells.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SARS-CoV-IN-2

Cat. No.: HY-135856

SARS-CoV-IN-2 is an effective inhibitor of **SARS-CoV** replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC_{50} of 1.9 μM in Vero cells.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SARS-CoV-IN-3

Cat. No.: HY-135858

SARS-CoV-IN-3 is an effective inhibitor of **SARS-CoV** replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC_{50} of 3.6 μM in Vero cells.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SARS-CoV-IN-4

Cat. No.: HY-143467

SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of **SARS-CoV nsp14 N7-methyltransferase**, with an IC_{50} of 0.6 μM (SARS-CoV nsp14).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone)

Cat. No.: HY-N0752

Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SDZ 224-015

Cat. No.: HY-141622

SDZ 224-015 is an orally active inhibitor of the **interleukin-1 beta (IL-1β)** converting enzyme and **caspase-1**. SDZ 224-015 possesses anti-COVID-19 activity, targeting M^{pro} (IC_{50} of 30 nM).
.

Purity: 95.49%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Setrobuvir

(ANA598)

Cat. No.: HY-13247

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV **NS5B** polymerase inhibitor. ANA-598 inhibits both de novo **RNA synthesis** and primer extension, with IC_{50}s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 **RdRp** and induces RdRp inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Silymarin

Cat. No.: HY-N7073

Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective **SARS-CoV-2 main protease (M^{pro})** inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance.

Silymarin

Purity: ≥80.0%
Clinical Data: Launched
Size: 250 mg, 500 mg

Simeprevir

(TMC435)

Cat. No.: HY-10241

Simeprevir (TMC435) is an oral and potent **HCV NS3/4A protease** inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC_{50} of 7.8 nM. Simeprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simeprevir-13C,d3

(TMC435-13C,d3)

Cat. No.: HY-10241S

Simeprevir-13C,d3 (TMC435-13C,d3) is the 13C- and deuterium labeled Simeprevir. Simeprevir (TMC435) is an oral and potent **HCV NS3/4A protease** inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC_{50} of 7.8 nM. Simeprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simpinicline

(OC-02)

Cat. No.: HY-139582

Simpinicline (OC-02), a highly selective **nicotinic acetylcholine receptor (nAChR)** agonist, shows potent antiviral activity against the SARS-CoV-2 variants in cell culture with an IC_{50} of 0.04 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sivelestat

(EI546; LY544349; ONO5046)

Cat. No.: HY-17443

Sivelestat (EI546) is a competitive inhibitor of **human neutrophil elastase**, with an IC_{50} of 44 nM and a K_i of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.



Purity: 98.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Sivelestat sodium

(ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium)

Cat. No.: HY-17443A

Sivelestat (EI546) sodium is a competitive inhibitor of **human neutrophil elastase**, with an IC_{50} of 44 nM and a K_i of 200 nM.



Purity: 99.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Sivelestat sodium tetrahydrate (EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ...)

Cat. No.: HY-17443B

Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of **human neutrophil elastase**, with an IC_{50} of 44 nM and a K_i of 200 nM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SP inhibitor 1

Cat. No.: HY-144647

SP inhibitor 1 (compound 34) is a selective **SARS-CoV-2 spike protein (SP)** inhibitor with an IC_{50} of 3.26 μM, >25 μM, >25 μM for SP, M^{pro} and PL^{pro} protein, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSAA09E2

Cat. No.: HY-138067

SSAA09E2 is an inhibitor of **SARS-CoV** (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of **SARS-S** with the receptor for **SARS-CoV**, Angiotensin Converting Enzyme-2 (ACE2) .



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Suramin

Cat. No.: HY-B0879

Suramin is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Suramin sodium salt

(Suramin hexasodium salt)

Cat. No.: HY-B0879A

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin sodium salt is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).

Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

TAPI-2

(TNF Protease Inhibitor 2)

Cat. No.: HY-100211

TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (**MMP**), tumour necrosis factorα-converting enzyme (**TACE**) and a disintegrin and metalloproteinase (**ADAM**), with an IC_{50} of 20 μM for MMP. TAPI-2 blocks the entry of infectious **SARS-CoV**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Telaprevir

(VX-950)

Cat. No.: HY-10235

Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease**, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.



Purity: 96.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Telaprevir-d4

(VX-950-d4)

Cat. No.: HY-10235S

Telaprevir-d4 (VX-950-d4) is the deuterium labeled Telaprevir.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TH1217

(ZINC1775962367)

Cat. No.: HY-135909

TH1217 (ZINC1775962367) is a potent and selective **dCTPase pyrophosphatase 1 (dCTPase)** inhibitor, with an IC_{50} of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thapsigargin

Cat. No.: HY-13433

Thapsigargin, an **endoplasmic reticulum (ER) stress** inducer, is an inhibitor of microsomal **Ca^{2+}-ATPase**. Thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tipranavir
(PNU-140690)

Cat. No.: HY-15148

Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of **HIV-1 protease**, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC_{50}s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Tipranavir-d4

Cat. No.: HY-15148S

Tipranavir-d4 (PNU-140690-d4) is the deuterium labeled Tipranavir. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of **HIV-1 protease**, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC_{50}s of 66-410 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Umifenovir

Cat. No.: HY-14904

Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an **anti-influenza virus** agent. Umifenovir could effectively inhibit the fusion of virus with host cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Umifenovir hydrochloride

Cat. No.: HY-14904A

Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an **anti-influenza virus** agent.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Umifenovir-d6 hydrochloride

Cat. No.: HY-14904AS

Umifenovir-d6 hydrochloride is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vanillinbananin

Cat. No.: HY-145117

Vanillinbananin is an effective inhibitor of the ATPase activity of the **SARS Coronavirus helicase** with an IC_{50} value of 0.68 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Velpatasvir
(GS-5816)

Cat. No.: HY-12530

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a **SARS-CoV $3CL^{pro}$** inhibitor with an IC_{50} of 2.16 μM.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Velpatasvir-d7

Cat. No.: HY-12530S

Velpatasvir-d7 (GS-5816-d7) is the deuterium labeled Velpatasvir. Velpatasvir (GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Verbenalin

Cat. No.: HY-N2014

Verbenalin is Verbena glycoside, with anti-inflammatory, anti-fungal anti-virus activities. Verbenalin can be used for the research of prostatitis. Verbenalin can reduce cerebral ischemia-reperfusion injury.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Vps34-IN-2

Cat. No.: HY-12473

Vps34-IN-2 is a novel, potent and selective inhibitor of **Vps34** with IC_{50}s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

X77

Cat. No.: HY-136298A

X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (**SARS-CoV-2 M^{pro}**). X77 binds to SARS-CoV-2 M^{pro} with a K_d value of 0.057 μM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XP-59

Cat. No.: HY-136284

XP-59 is a potent inhibitor of the **SARS-CoV M^{pro}**, with a K_i of 0.1 μM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XR8-69

Cat. No.: HY-139892

XR8-69 is a **SARS-CoV-2 PLpro** inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YH-53

Cat. No.: HY-139311

YH-53 is a potent **3CL^{pro}** inhibitor with K_i values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL^{pro} and SARS-CoV-2 3CL^{pro}, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Z-FA-FMK

((1S)-Z-FA-FMK)

Cat. No.: HY-P0109A

Z-FA-FMK ((1S)-Z-FA-FMK; Compound 6) is a broad-spectrum halomethyl ketone inhibitor sgainst Coronavirus (**SARS-CoV**) main protease **3CL** with a K_i of 25.7 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Z-LVG-CHN2

Cat. No.: HY-108137

Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of **cysteine proteinase**. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Zotatifin

(eFT226)

Cat. No.: HY-112163

Zotatifin (eFT226) is a potent, selective, and well-tolerated **eIF4A** inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5′-UTRs (IC_{50}=2 nM) and interferes with the assembly of the eIF4F initiation complex.



Purity: 99.58%
Clinical Data: Phase 2
Size: 1 mg, 2 mg, 5 mg

αGalCer-RBD

Cat. No.: HY-144120

αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against **SARS-CoV-2** and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg